Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA under pressure for BPA safety

This article was originally published in The Tan Sheet

Executive Summary

Following a Sept. 17 study in the Journal of American Medical Association that finds higher concentrations of Bisphenol A in human urine is associated with cardiovascular disease, diabetes and liver-enzyme abnormalities, Reps. Rosa DeLauro, D-Conn., and John Dingell, D-Mich., criticize FDA's determination that BPA in food lining containers is safe. DeLauro says in a Sept. 16 release that FDA's stance on BPA's safety is "perplexing and dangerous." Likewise, Dingell urged the agency to "take careful notice of this new research during its Science Board meeting on Bisphenol A" Sept. 16, according to a same-day release. The most recent JAMA study does not conclusively link BPA in food containers as a cause of the associated diseases

You may also be interested in...

Science Board looks at BPA, contaminants

The FDA advisory group receives information on current methods for detecting contaminants in agency-regulated products and plans to discuss a subcommittee's review of bisphenol A use in food contact applications at an upcoming meeting. Although FDA has determined that BPA lining food containers is safe, a September study in the Journal of American Medical Association found higher concentrations of the substance in human urine is associated with cardiovascular disease, diabetes and liver-enzyme abnormalities (1"The Tan Sheet" Sept. 22, 2008, In Brief). In an Oct. 9 Federal Register notice, FDA says the board also will discuss its 2009 agenda topics during the meeting scheduled for Oct. 31 at the Washington, DC North/Gaithersburg Hilton in Gaithersburg, Md. The agency says background material on the topics should be available at least two days before the meeting

Did Sarepta Need To Tell Investors About Its Vyondys 53 Dispute Resolution Request?

Attorneys say Sarepta did not have an obligation to report its appeal, particularly since winning a formal dispute filing with the US FDA is a long shot.

Sarepta’s Vyondys: Renal Toxicity Concerns That Delayed Approval Get Enhanced Postmarketing Scrutiny, Label Warning

Sarepta must perform enhanced pharmacovigilance for serious renal toxicity events and rhabdomyolysis with the Duchenne muscular dystrophy drug, which carries a label warning for renal toxicity. Approval letter includes 2024 target completion date for ESSENCE confirmatory trial.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts